Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/13/2025

Approach to Managing Glaucoma

Definition and Pathophysiology

  • Glaucoma is a chronic, progressive optic neuropathy characterized by damage to the optic nerve, death of retinal ganglion cells, and loss of retinal nerve fiber layer (RNFL), resulting in progressive visual field loss 3, 2
  • It is the second leading cause of blindness worldwide after cataracts, with an estimated 76 million people affected globally in 2020 4, 2
  • Primary open-angle glaucoma (POAG) is the most common form, characterized by open anterior chamber angles and optic nerve damage with or without elevated IOP 1, 5

Risk Factors

  • Elevated intraocular pressure (IOP) - the only modifiable risk factor 2
  • Older age 2
  • Family history of glaucoma 2
  • African race or Latino/Hispanic ethnicity 2
  • Thin central corneal thickness 2
  • Low ocular perfusion pressure 2

Diagnostic Approach

  • Complete ocular history (refractive error, trauma, prior surgery) 1
  • Family history of glaucoma, including severity and outcomes 1
  • Systemic history (asthma/COPD, migraine, Raynaud's syndrome, diabetes, cardiovascular disease) 1
  • Race/ethnicity assessment 1
  • Intraocular pressure (IOP) measurement with multiple readings at different times of day 6
  • Gonioscopy to assess anterior chamber angle and exclude angle closure or secondary causes 6
  • Central corneal thickness (CCT) measurement, as thinner corneas are associated with higher risk of progression 6
  • Optic nerve head (ONH) examination to identify structural changes 6
  • Retinal nerve fiber layer (RNFL) assessment 6
  • Visual field testing using standard automated perimetry (SAP) 1
  • Structural imaging: Stereoscopic optic disc photography 6, Optical coherence tomography (OCT) of ONH, RNFL, and macular ganglion cell complex 6

Classification of Glaucoma Severity

  • Mild: Definite optic disc, RNFL, or macular imaging abnormalities with normal visual field on standard automated perimetry 2
  • Moderate: Definite optic disc, RNFL, or macular imaging abnormalities with visual field abnormalities in one hemifield not within 5 degrees of fixation 2
  • Severe: Definite optic disc, RNFL, or macular imaging abnormalities with visual field abnormalities in both hemifields and/or loss within 5 degrees of fixation in at least one hemifield 2

Management Approach

  • Control IOP in the target range 3
  • Maintain stable optic nerve/RNFL status 3
  • Preserve stable visual fields 3
  • Maintain quality of vision and preserve quality of life 2
  • Target IOP should be individualized based on stage of glaucoma damage, baseline IOP, age, and additional risk factors 2, 5
  • Lowering pretreatment IOP by 25% or more has been shown to slow progression of POAG 5

Monitoring and Follow-up

  • Untreated low-risk patients: Follow-up every 12-24 months 6
  • Treated or high-risk patients: More frequent follow-up (every 3-6 months) until stable 6
  • Each follow-up visit should include visual acuity measurement 2, slit-lamp biomicroscopy 8, IOP measurement 2, and periodic ONH and RNFL evaluation 6

Quality of Life Impact

  • Glaucoma can significantly impact quality of life, affecting daily activities like reading, walking, and driving 4
  • Performance deteriorates with worsening glaucoma severity or when both eyes are affected 4
  • People with glaucoma are more likely to experience falls and motor vehicle collisions 4
  • Direct medical costs for glaucoma in the US are estimated at nearly $3 billion annually 4